A novel series of fifteen 3-(3,4-dihydroisoquinolin-2($1H$)-yl)-𝑁-(substituted phenyl) propanamides 3(a-o) were synthesized by reacting the corresponding 3-chloro-𝑁-(aryl) propanamides 2(a-o) with 1,2,3,4-tetrahydroisoquinoline 1 in acetonitrile. The compounds have been characterized on the basis of elemental analysis and spectral data. All the compounds were evaluated for their HIV-1 RT inhibitory activity. Among the synthesized compounds, 3-(3,4-dihydroisoquinolin-2($1H$)-yl)-𝑁-𝑜-tolyl propanamide 3d and 3-(3,4-dihydroisoquinolin-2(1H)-yl)-𝑁-(2,4,6-tribromophenyl)propanamide 3f were identified as significant inhibitors of HIV-1 reverse transcriptase with 56% and 43% residual RT activity respectively at the final concentration of 40 𝜇M when compared with the standard drug Efavirenz. Docking studies with HIV-1 RT (PDB ID 1rt2) were also performed in order to investigate the binding pattern of these compounds.

2-[5-substituted-1-𝐻-benzo(d)imidazol-2-yl sulfinyl]methyl-3-substituted quinazoline-4-(3𝐻)-one derivatives were synthesized and tested for antiulcer activity against pylorus ligation-induced, aspirin induced and ethanol induced ulcer in rat model. All the synthesized compounds were characterized by using IR, MS and ¹H NMR spectral and elemental analysis. The compounds were scramed for their antiulcer activity: compounds 5k and 5n showed higher activity than omeprazole used as standard.